अApnaFunda
Menu

TTK HEALTHCARE LTD (TTKHLTCARE)

Health Technology · Pharmaceuticals: Major · figures to Nov '26

Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.47 / 100
Profitability 22Growth 19Balance sheet 100
Momentum scoreHow strong the recent trend is: 3-month price change, 12-month improvement in earnings and the rise in FII + DII holding, among companies above ₹500 cr.57 / 100
Price 32Earnings 60FII/DII 79

Passes these screensValue PickLittle growth priced in

Compare withSUN PHARMACEUTICAL INDUSTRIESDIVIS LABORATORIESTORRENT PHARMACEUTICALS

Share price

Closing priceAdjusted for splits and bonus issues.

₹927.55 latest close · +0.5% over the last 90 sessions

₹900₹1,000₹1,100₹1,200Jul 3Jul 29Aug 24Sep 17Oct 14Nov 9 ₹900₹1,000₹1,100₹1,200Jul 3Sep 4Nov 9

₹927.55 month-end · −16.7% over 12 months

₹800₹1,000₹1,200Nov '25Jan '26Apr '26Jun '26Sep '26Nov '26 ₹800₹1,000₹1,200Nov '25May '26Nov '26

₹927.55 month-end · −32.2% over 3 years

₹1,000₹1,500Nov '23Jun '24Jan '25Sep '25Apr '26Nov '26 ₹1,000₹1,500Nov '23May '25Nov '26

₹927.55 month-end · +26.4% since Jan '19

₹500₹1,000₹1,500Jan '19Aug '20Mar '22Sep '23Apr '25Nov '26 ₹500₹1,000₹1,500Jan '19Dec '22Nov '26

52-week range ₹735.00 to ₹1247.00 · 1-year volatility 33.7%

Was the rally earned?

-17%share price, 1 yearLower P/E held it back

Earnings helped, the multiple did not.

  • Per-share earnings added 15 points, but investors now pay less per rupee of profit (P/E 25.0x to 17.7x), which took 31 points back.
  • The share count barely moved.
Net profit growth: +15 pts. Points of the price return explained by net profit growing (or shrinking).+15 ptsNet profit growthP/E change: −31 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−31 ptsP/E changeShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0 ptsShare count changeShare price: −17%−17%Share priceNet profit growth: +15 pts. Points of the price return explained by net profit growing (or shrinking).+15ProfitP/E change: −31 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−31P/EShare count change: 0 pts. Points of the price return explained by the share count changing. More shares count against the price.0SharesShare price: −17%−17%Share price
Net profit growth+15 ptsNet profit rose about 17%, which lifts the price.
P/E change-31 ptsThe P/E fell from 25.0x to 17.7x, which lowers the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
-32%share price, 3 yearsEarnings-driven

Mostly earnings.

  • Per-share earnings took off 179 points, while the multiple moved less (P/E 3.0x to 17.7x).
  • The share count barely moved.
Net profit growth: −179 pts. Points of the price return explained by net profit growing (or shrinking).−179 ptsNet profit growthP/E change: +147 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+147 ptsP/E changeShare price: −32%−32%Share priceNet profit growth: −179 pts. Points of the price return explained by net profit growing (or shrinking).−179ProfitP/E change: +147 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+147P/EShare price: −32%−32%Share price
Net profit growth-179 ptsNet profit fell about 88%, which lowers the price.
P/E change+147 ptsThe P/E rose from 3.0x to 17.7x, which lifts the price.
Share count change0 ptsShare count was little changed. More shares would count against the price.
+38%share price, 5 yearsLower P/E held it back

Mostly yes, with a catch.

  • Per-share earnings added 55 points, but investors now pay less per rupee of profit (P/E 20.5x to 17.7x), which took 17 points back.
  • The share count barely moved.
Net profit growth: +56 pts. Points of the price return explained by net profit growing (or shrinking).+56 ptsNet profit growthP/E change: −17 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−17 ptsP/E changeShare count change: −1 pts. Points of the price return explained by the share count changing. More shares count against the price.−1 ptsShare count changeShare price: +38%+38%Share priceNet profit growth: +56 pts. Points of the price return explained by net profit growing (or shrinking).+56ProfitP/E change: −17 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.−17P/EShare count change: −1 pts. Points of the price return explained by the share count changing. More shares count against the price.−1SharesShare price: +38%+38%Share price
Net profit growth+56 ptsNet profit rose about 61%, which lifts the price.
P/E change-17 ptsThe P/E fell from 20.5x to 17.7x, which lowers the price.
Share count change-1 ptsShare count was little changed. More shares would count against the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-67.7%recovered 2022-09
1-year volatility33.7%annualised
Beta vs sector index0.613-year daily, correlation 0.29
Volume spikes21last 90 sessions, 5x the 50-day median

Drawdown from peak

0%−20%−40%−60%2020202120222023202420252026−65.8% 0%−20%−40%−60%2020202220242026−65.8%
Largest drawdowns

-67.7% (2019-01 peak to 2020-03 low, recovered 2022-09)

-59.9% (2024-09 peak to 2026-03 low, not yet recovered)

-17.6% (2022-12 peak to 2023-03 low, recovered 2023-03)

Most recent volume spikes

2026-10-30: 18.2x the 50-day median, price -13.7% that day

2026-09-09: 10.8x the 50-day median, price -0.6% that day

2026-09-08: 9.8x the 50-day median, price +9.2% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

17.7xP/E todayNear its historic low
Against its own history16th percentile
CheapestMedian 25.3xDearest

Usual range 3.3x to 52.4x since 2019-01.

Against Health Technology17.7x vs 37.0x
This company
17.7x
Sector median
37.0x

52% below the Health Technology median.

2.6x29.2x55.8x82.4xJan '19Aug '20Mar '22Oct '23May '25Nov '262.6x29.2x55.8x82.4xJan '19Sep '21May '24Nov '26
P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median
How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

  • ROCE29thflat vs a year ago
  • Op. margin15thflat vs a year ago
  • Revenue growth37th▼ 13 pts vs a year ago
  • EPS growth61st▲ 37 pts vs a year ago
  • Debt/equity ↓84thflat vs a year ago
  • Cash cycle ↓85th▼ 4 pts vs a year ago
  • P/E ↓81st▲ 14 pts vs a year ago
  • 12M momentum20th▼ 18 pts vs a year ago

Rank history

ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26
Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~2%annual earnings growth implied by the priceBelow delivered growth

At normalised P/E (five-year average earnings) of 7.3x, a holder earning 12%/yr needs earnings to grow about 2.1%/yr for 10 years, then trade at 15x.

Delivered15.9%/yrEPS, last 10 fiscal years · 3-yr avg to 3-yr avg
Gap−13.7 ptsimplied minus delivered
Rank744thmost demanding of 856

Over time

Implied growth by month (solid) and delivered growth (dashed).

-19%10%39% Jan 2019Nov 2026 -19%10%39% Jan 2019Nov 2026

Change the assumptions

Exit P/E / return11%12%13%
12x3.3%4.2%5.1%
15x1.2%2.1%3.1%
20x−1.4%−0.5%0.4%

Drag a slider to test other assumptions

Implied: 2.1%/yr

Looking back

  • Jan 2020Price implied 21%/yr; EPS has since grown 16%/yr (7.0 yrs)
  • Jan 2021Price implied 22%/yr; EPS has since grown 33%/yr (6.0 yrs)
  • Jan 2022Price implied 22%/yr; EPS has since grown 8%/yr (5.0 yrs)

Past comparisons cover only companies listed today (survivorship bias) and say nothing about future outcomes.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov
₹927.55
P/E
17.7x
ROCE
8.0%
Market Cap
₹1311 cr
Revenue (TTM)
₹889 cr
P/S
1.5x
P/B
1.2x
ROE
6.6%
Operating Margin
6.0%
Debt / Equity
0.0x
Promoter Holding
74.6%
12M Momentum
-16.7%

52-week range

₹735.00₹1247.00
38% of the way from its 52-week low to its high

Price risk

1Y volatility
33.7%
Beta vs sector
1-year daily
0.67

Balance sheet & cash

Interest cover
operating profit ÷ interest
24.3x
Cash from profit, 3Y
operating cash flow ÷ net profit
-0.14x
low
Share count, 1Y
unchanged

Are profits backed by cash?

4 of 7checks within range2 beyond a threshold
Other income reliance71%Beyond threshold

Other income as a share of pre-tax profit (trailing twelve months): 71.3%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate26%Within range

Median quarterly effective tax rate over about 2.5 years: 26.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion-0.14xBeyond threshold

Operating cash flow divided by net profit over the last three fiscal years: -0.14x (cash from operations ₹-30 cr, net profit ₹211 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow2 of 5 yrsNear threshold

Fiscal years with positive free cash flow in the last 5: 2. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+5 daysWithin range

Debtor days are above the median of the previous three fiscal years by 5 days (47 vs 42). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress1% of fixed assetsWithin range

Capital work-in-progress is 1% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days-27 days / 2 yrsWithin range

Days payable changed by -27 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 2 years, DIIs trimmed 0.9 pts.
  • The number of shareholders rose from 16,651 to 22,809 (+37%) between Dec 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupDec '23Jun '26Change
Promoters74.6%74.6%0.0 pts
FIIs1.9%1.9%0.0 pts
DIIs3.1%2.2%-0.9 pts
Public and others20.5%21.4%+0.9 pts

Number of shareholders

22,809shareholders+37% since Dec '23
16k18k21k24k Dec '23Jun '24Mar '25Sep '25Mar '26Jun '26
Dec '23: 16,651
Mar '24: 17,221
Jun '24: 16,930
Sep '24: 15,762
Mar '25: 15,899
Jun '25: 16,112
Sep '25: 16,134
Dec '25: 22,481
Mar '26: 23,686
Jun '26: 22,809
 16k18k21k24k Dec '23Sep '24Sep '25Jun '26
Dec '23: 16,651
Mar '24: 17,221
Jun '24: 16,930
Sep '24: 15,762
Mar '25: 15,899
Jun '25: 16,112
Sep '25: 16,134
Dec '25: 22,481
Mar '26: 23,686
Jun '26: 22,809

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

+2.8%typical 12-month return vs the marketNot meaningfully different from the base rate
  • We found 50 past situations where a non-financial company looked like TTK HEALTHCARE LTD today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −13% to +37% vs the market, against −1% for all non-financial companies in the same months.
  • The gap against the base rate (+4.0%, 80% range −1.1% to +18.6%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

−50%0%+50%+100%
TVTODAY · Aug 2024: −41.1% vs market
KIRLOSENG · Mar 2021: −34.7% vs market
LUXIND · Sep 2024: −32.5% vs market
LXCHEM · May 2025: −29.0% vs market
VARDHACRLC · Apr 2023: −25.1% vs market
BALMLAWRIE · Feb 2021: −22.0% vs market
EXCELINDUS · Aug 2025: −21.2% vs market
NOCIL · Jan 2024: −19.9% vs market
FMGOETZE · Jul 2023: −16.8% vs market
MAYURUNIQ · Nov 2023: −14.6% vs market
JTEKTINDIA · Aug 2025: −14.1% vs market
BLISSGVS · Jun 2023: −13.7% vs market
IMPAL · Aug 2020: −13.2% vs market
RALLIS · Apr 2024: −13.0% vs market
PODDARMENT · Mar 2023: −8.4% vs market
SESHAPAPER · Sep 2025: −5.2% vs market
AVANTIFEED · Mar 2023: −4.0% vs market
BBL · Jun 2020: −2.2% vs market
ALBERTDAVD · May 2022: −1.7% vs market
HINDCOMPOS · Jun 2023: −0.9% vs market
AIRAN · Jul 2023: −0.4% vs market
PLASTIBLEN · Jul 2023: −0.1% vs market
SHRIPISTON · Nov 2021: +1.3% vs market
IOLCP · Feb 2025: +1.4% vs market
SANDESH · May 2020: +1.4% vs market
FDC · Jan 2024: +4.1% vs market
WONDERLA · May 2021: +6.2% vs market
VSSL · Mar 2025: +7.1% vs market
ARE&M · Jan 2023: +12.8% vs market
ORIENTCER · Jun 2023: +17.9% vs market
CLEDUCATE · Aug 2024: +23.1% vs market
KRSNAA · Mar 2024: +23.7% vs market
PPAP · Jul 2020: +25.0% vs market
SREEL · Sep 2025: +26.2% vs market
RAMCOIND · May 2020: +29.3% vs market
IFGLEXPOR · Feb 2020: +32.6% vs market
INDNIPPON · Feb 2023: +36.4% vs market
STARCEMENT · Jun 2022: +37.4% vs market
KRBL · Jul 2022: +38.8% vs market
GAEL · Oct 2025: +39.2% vs market
WINDLAS · Jan 2023: +42.9% vs market
AMBIKCO · Jan 2021: +45.5% vs market
CHEMBOND · Oct 2022: +63.1% vs market
HONDAPOWER · Mar 2022: +71.9% vs market
BOROLTD · Sep 2021: +74.4% vs market
GUJALKALI · Aug 2021: +82.5% vs market
KIRLOSIND · May 2020: +89.2% vs market
GABRIEL · Nov 2024: +123.5% vs market
DBCORP · Oct 2022: +142.6% vs market
BORORENEW · Jan 2020: +289.7% vs market
Similar setups +2.8%All companies −1.2%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 3 beyond the range shown, drawn at the edge

Similar setups' median
+2.8%
All companies' median
−1.2%
Beat the market
56% vs 49%

50 past situations · 50 companies · 37 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
INDNIPPON
Producer Manufacturing		 Feb 2023 16x10% −17%−27% +36%
SREEL
Consumer Non-Durables		 Sep 2025 25x7% −21%−21% +26%
IMPAL
Distribution Services		 Aug 2020 14x5% +3%−21% −13%
PLASTIBLEN
Process Industries		 Jul 2023 21x9% +3%−8% 0%
IFGLEXPOR
Producer Manufacturing		 Feb 2020 10x8% −32%−41% +33%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
VARDHACRLC
Consumer Non-Durables		 Apr 2023 27x6% −16%−18% −25%
GUJALKALI
Process Industries		 Aug 2021 19x5% +33%−11% +83%
TVTODAY
Consumer Services		 Aug 2024 29x11% +21%−5% −41%
How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: drawdown from 12-month high, 12-month momentum and P/E. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to TTK HEALTHCARE LTD. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

DEN NETWORKSDEN
Consumer Services
66%similar
volatilitymarket cap
NUCLEUS SOFTWARE EXPORTSNUCLEUS
Technology Services
65%similar
revenuevolatility
TCI EXPRESSTCIEXP
Transportation
59%similar
market capEPS growth
BOROSIL SCIENTIFICBOROSCI
Producer Manufacturing
57%similar
debt/equityoperating margin
HATHWAY CABLE & DATACOM LIMITEHATHWAY
Consumer Services
57%similar
revenue growthmarket cap
ANUH PHARMAANUHPHR
Health Technology
59%similar
P/Erevenue
THEMIS MEDICARETHEMISMED
Health Technology
34%similar
market capP/E
WINDLAS BIOTECHWINDLAS
Health Technology
31%similar
revenuedebt/equity

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Mar '23

  1. OctPriceVolume reached 18.2x its 50-day median on 2026-10-30; price -13.7% that day.
  2. SepResultsYear-on-year EPS growth turned positive.
  3. SepPeer rankMoved into the 2nd quartile of Health Technology on EPS growth (from the 3rd quartile).
  4. JulPriceVolume reached 69.1x its 50-day median on 2026-07-13; price +7.9% that day.
  5. AprPriceVolume reached 9.7x its 50-day median on 2026-04-09; price -2.6% that day.
  6. MarPriceFell 60% from the Sep 2024 peak to the Mar 2026 low.
  7. JanPriceVolume reached 9.7x its 50-day median on 2026-01-07; price +0.3% that day.
  8. DecPeer rankMoved into the 3rd quartile of Health Technology on EPS growth (from the bottom quartile).
Show 22 earlier events
  1. OctPriceVolume reached 6.5x its 50-day median on 2025-10-17; price +3.2% that day.
  2. SepResultsYear-on-year EPS growth turned negative.
  3. SepPeer rankSlipped to the bottom quartile of Health Technology on EPS growth (from the top quartile).
  4. JulPriceVolume reached 8.1x its 50-day median on 2025-07-02; price +6.7% that day.
  5. JunResultsYear-on-year EPS growth turned positive.
  6. JunPeer rankMoved into the top quartile of Health Technology on EPS growth (from the bottom quartile).
  7. JunPriceVolume reached 8.7x its 50-day median on 2025-06-10; price +7.2% that day.
  8. MarPriceVolume reached 37.3x its 50-day median on 2025-03-17; price +0.9% that day.
  9. OctPriceVolume reached 6.7x its 50-day median on 2024-10-07; price -1.5% that day.
  10. AugPriceVolume reached 24.9x its 50-day median on 2024-08-02; price +1.7% that day.
  11. JunResultsYear-on-year EPS growth turned negative.
  12. JunPeer rankSlipped to the bottom quartile of Health Technology on EPS growth (from the top quartile).
  13. MayPriceVolume reached 5.9x its 50-day median on 2024-05-24; price -0.1% that day.
  14. FebPriceVolume reached 24.7x its 50-day median on 2024-02-06; price +6.3% that day.
  15. DecPriceVolume reached 14.5x its 50-day median on 2023-12-21; price +6.0% that day.
  16. AugPriceVolume reached 7.7x its 50-day median on 2023-08-01; price +2.5% that day.
  17. JunResultsYear-on-year EPS growth turned positive.
  18. JunValuationP/E fell below the 10th percentile of its own history to date (2.8x).
  19. JunPeer rankMoved into the top quartile of Health Technology on EPS growth (from the 3rd quartile).
  20. JunDividendDividend payout cut from 34% to 2% of profit.
  21. AprPriceVolume reached 118.4x its 50-day median on 2023-04-06; price +3.0% that day.
  22. MarPriceVolume reached 31.8x its 50-day median on 2023-03-24; price +13.0% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history60 months · 2021-12 to 2026-11
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-1117.7x₹889 cr6.6%8.0%0.0x
2026-1017.3x₹889 cr6.6%8.0%0.0x
2026-0919.5x₹889 cr6.6%8.0%0.0x
2026-0825.0x₹857 cr5.9%8.0%0.0x
2026-0722.0x₹857 cr5.9%8.0%0.0x
2026-0619.7x₹857 cr5.9%8.0%0.0x
2026-0521.0x₹829 cr5.6%9.0%0.0x
2026-0421.3x₹829 cr5.6%9.0%0.0x
2026-0317.4x₹829 cr5.6%9.0%0.0x
2026-0219.4x₹825 cr6.2%9.0%0.0x
2026-0120.6x₹825 cr6.2%9.0%0.0x
2025-1222.1x₹825 cr6.2%9.0%0.0x
2025-1125.0x₹819 cr5.9%9.0%0.0x
2025-1026.4x₹819 cr5.9%9.0%0.0x
2025-0925.8x₹819 cr5.9%9.0%0.0x
2025-0820.0x₹801 cr7.7%9.0%0.0x
2025-0721.5x₹801 cr7.7%9.0%0.0x
2025-0622.1x₹801 cr7.7%9.0%0.0x
2025-0520.5x₹792 cr8.4%9.0%0.0x
2025-0420.1x₹792 cr8.4%9.0%0.0x
2025-0320.1x₹792 cr8.4%9.0%0.0x
2025-0220.7x₹771 cr8.0%9.0%0.0x
2025-0122.8x₹771 cr8.0%9.0%0.0x
2024-1224.9x₹771 cr8.0%9.0%0.0x
2024-1126.9x₹759 cr7.9%9.0%0.0x
2024-1027.6x₹759 cr7.9%9.0%0.0x
2024-0930.0x₹759 cr7.9%9.0%0.0x
2024-0835.7x₹753 cr6.3%9.0%0.0x
2024-0735.1x₹753 cr6.3%9.0%0.0x
2024-0633.1x₹753 cr6.3%9.0%0.0x
2024-053.3x₹725 cr67.2%10.0%0.0x
2024-043.5x₹725 cr67.2%10.0%0.0x
2024-033.3x₹725 cr67.2%10.0%0.0x
2024-023.3x₹725 cr67.2%10.0%0.0x
2024-013.3x₹725 cr67.2%10.0%0.0x
2023-123.1x₹725 cr67.2%10.0%0.0x
2023-113.0x₹725 cr67.2%10.0%0.0x
2023-102.7x₹725 cr67.2%10.0%0.0x
2023-092.6x₹725 cr67.2%10.0%0.0x
2023-082.6x₹725 cr67.2%10.0%0.0x
2023-072.7x₹725 cr67.2%10.0%0.0x
2023-062.8x₹725 cr67.2%10.0%0.0x
2023-0543.2x₹599 cr12.7%8.0%0.1x
2023-0442.6x₹599 cr12.7%8.0%0.1x
2023-0335.3x₹599 cr12.7%8.0%0.1x
2023-0231.0x₹599 cr12.7%8.0%0.1x
2023-0133.4x₹599 cr12.7%8.0%0.1x
2022-1234.2x₹599 cr12.7%8.0%0.1x
2022-1131.0x₹599 cr12.7%8.0%0.1x
2022-1029.4x₹599 cr12.7%8.0%0.1x
2022-0931.9x₹599 cr12.7%8.0%0.1x
2022-0829.5x₹599 cr12.7%8.0%0.1x
2022-0728.9x₹599 cr12.7%8.0%0.1x
2022-0626.8x₹599 cr12.7%8.0%0.1x
2022-0522.4x₹476 cr15.6%6.0%0.1x
2022-0423.3x₹476 cr15.6%6.0%0.1x
2022-0325.3x₹476 cr15.6%6.0%0.1x
2022-0220.4x₹476 cr15.6%6.0%0.1x
2022-0120.8x₹476 cr15.6%6.0%0.1x
2021-1221.5x₹476 cr15.6%6.0%0.1x

Older months are in the live observatory.

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback